Cipla Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 650% at ₹13/Share	05-Jun-2026	05-Jun-2026
DividendsSpecial Dividend of 150% at ₹3/Share	27-Jun-2025	27-Jun-2025
DividendsFinal Dividend of 650% at ₹13/Share	27-Jun-2025	27-Jun-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
HDFC Conservative Hybrid Fund - Growth	80.00 k	80.00 k no change
Aditya Birla Sun Life Retirement Fund - The 50s Plan - Regular Plan - Growth	318	318 no change
iSIF Active Asset Allocator Long-Short Fund - Regular Plan - Growth	25.00 k	- (100%)
Zerodha Nifty LargeMidcap250 Plus 8-13 yr G-Sec 70:30 Index Fund - Growth - Direct Plan	194	- (100%)
Zerodha Nifty LargeMidcap 250 Index Fund - Growth - Direct Plan	32.94 k	- (100%)

CA Barkha Kamra

3 Oct • 1:16 PM · SEBI-Registered Analyst

Cipla Pharma Pune Unit Drug Sale Licence Cancelled

The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale and distribution licences of the Carrying and Forwarding (C&F) warehouse of Cipla Pharma & Life Sciences Ltd

CIPLA

at Wadki in Pune, citing alleged regulatory violations. The fresh cancellation order was issued on October 1, 2026, after the regulator completed proceedings directed by the Bombay High Court. Reactin Plus Tablets The case primarily relates to Reactin Plus Tablets, a Schedule H prescription medicine. According to the FDA, inspections found that the medicine’s packaging carried promotional or therapeutic claims, including the words “Analgesic and Antipyretic,” which the regulator considered inconsistent with applicable provisions of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The FDA also cited alleged deficiencies involving storage conditions, documentation, inventory management and the handling of expired medicines. Regulatory dispute The regulatory dispute has a significant procedural history. An earlier licence cancellation issued in August was withdrawn after the Bombay High Court questioned the procedure followed by the FDA and directed that Cipla be given a proper opportunity to respond. The regulator subsequently issued a revised show-cause notice on September 4. Cipla submitted its written response on September 11 and was granted a personal hearing on September 21. After reviewing the company’s submissions and inspection records, the FDA issued the fresh cancellation order. Cipla’s response Cipla has described the latest decision as disappointing and said it is reviewing the order. Importantly, the company has maintained that the regulatory action does not raise concerns about the safety, quality or efficacy of its medicines or indicate a patient-safety issue. The development highlights the increasing regulatory focus on compliance across pharmaceutical packaging, warehousing, documentation and distribution operations.

Vimal K

24 Sep • 11:59 PM · SEBI-Registered Analyst

Nifty Outlook for 24-Sep-2026 Looks Bearish

NIFTY 50 is expected to trade with a bearish bias on Friday, 25 September 2026, following a massive 1.64% single-session plunge that wiped out key psychological support the previous swing low of 23070.15 made in June 2026 on weekly charts. The Daily MACD below zero and the Hourly MACD below zero indicates a clear bearish trend. The Daily and Hourly RSI 14 below 50 also indicates a bearish trend. Thus, the overall trend of Nifty looks bearish, and the sellers are in control over the markets. Sell on rise would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a change in trend only if the price sustains above the resistance level. Can Initiate buying only if prices continue to sustain above the resistance level. I have provided Nifty Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Nifty Spot Resistance 1 - 23205 Resistance 2 - 23235 Support 1 - 22940 Support 2 - 22915 Happy Learning, Happy Trading and have a wonderful day. Top Gainers : CIPLA, ONGC, NTPC.

CIPLA

Amit Malviya

24 Sep • 6:49 PM · SEBI-Registered Analyst

Sensex down 1,247 pts as crude spikes past $105

Indian markets closed sharply lower today, 24 Sept 2026, as crude oil surged past $105 per barrel and U.S. bond yields hit 5.11%. The Sensex fell 1,247 points (−1.67%) to 73,580.54 and Nifty slipped 383 points (−1.64%) to 23,063.10, with all major sectors ending in the red. 📉 Market Summary – 24 Sept 2026 Index Close Change % Change Sensex 73,580.54 −1,247.71 −1.67% Nifty 50 23,063.10 −383.70 −1.64% Bank Nifty 55,710 (est.) −1.7% — Midcap 100 — −2.25% — Smallcap 100 — −1.53% — Rupee: Closed at ₹95.96 against USD, down 23 paise. Brent Crude: Jumped 2.36% to $105.4 per barrel. 🔍 Key Market Drivers Global Yields & Crude Spike: U.S. 10‑year Treasury yield at 5.11% and Brent crude above $105 triggered risk‑off sentiment. Geopolitical Tensions: Renewed U.S.–Iran friction and Middle East uncertainty kept investors cautious. Sector Sell‑off: Private banks, financials, autos, and metals led declines; defensives like pharma and IT fell less. FII & DII Flows: Despite yesterday’s buying (FIIs ₹1,617 cr, DIIs ₹2,341 cr), today’s global shock overrode domestic support. 🏦 Top Losers & Gainers Losers: Bajaj Finance (−5.47%), Axis Bank (−4.67%), Bajaj Finserv (−4.06%), InterGlobe Aviation (−2.78%), M&M (−2.31%).

CIPLA

Gainers:. Cipla (+0.8%), NTPC (flat to +0.2%) All sectoral indices closed negative: Private Bank: −2.2% Metal: −1.9% Auto: −1.5% Infra: −1.5% Oil & Gas: −1.3% FMCG: −1% 🧭 Technical Outlook Nifty: Formed a strong bearish candle; RSI below 40 shows weak momentum. Support: 23,000 – 22,950 Resistance: 23,600 – 23,650 Bank Nifty: Under pressure below 55,800; needs short‑covering for reversal. Trend: Negative until meaningful buying emerges; oversold zone may invite technical bounce near support. 🏢 Corporate Highlight NSE IPO Debut: National Stock Exchange listed today at ₹1,800 and closed at ₹1,818 (+1.85% vs ₹1,785 IPO price), valued at ₹4.49 lakh crore — India’s second‑largest IPO after Hyundai Motor India (2024).

AKANSHA JAIN

24 Sep • 5:29 PM · SEBI-Registered Analyst

Cipla: Relative strength stands out in today's weak Nifty

CIPLA

Limited is one of the Nifty 50 stocks standing out on September 24 as the broader market came under heavy selling pressure. The Nifty 50 closed at 23,063.10, down 383.70 points or 1.64%, while the Sensex declined 1.67%. Banking, metals and auto stocks were among the major areas of weakness. Against this backdrop, Cipla finished among the Nifty's strongest performers, gaining around 1.16% to ₹1,399. This relative strength is important because the stock managed to remain positive despite a broad risk-off session. The question now is whether this strength can sustain beyond one session. From a fundamental perspective, Cipla's performance needs to be tracked through its India business, US generics, respiratory portfolio, product launches and margin trajectory. For a pharmaceutical company, regulatory developments and product-specific opportunities can also materially influence quarterly performance. From a technical perspective, ₹1,400 is now an important psychological level after today's close near that mark. A sustained move above ₹1,400 with improving volumes would provide stronger confirmation that buyers are defending the stock despite broader market weakness. On the downside, today's low becomes the first reference point. If the stock starts giving back today's gains while the Nifty remains weak, the relative-strength setup would need to be reassessed. Another factor worth watching is sector rotation. During today's session, Cipla, SBI Life, BEL and NTPC were among the Nifty names showing resilience, while financial stocks such as Bajaj Finance, HDFC Life and Axis Bank faced significant selling. In a market where the Nifty fell 1.64%, Cipla's positive close makes its relative strength worth monitoring. The next few sessions will determine whether today's resilience develops into a sustained trend. Disclosure: I have no holding or financial interest in Cipla Limited at the time of writing.

CIPLA

Priyam Mehta

22 Sep • 10:15 AM · SEBI-Registered Analyst

Pfizer: Why the Cipla partnership matters

PFIZER

# Pfizer: Why the Cipla partnership matters Pfizer Limited has partnered with Cipla to expand the reach of four established brands in India. The deal shows how Pfizer is using a stronger distribution network while retaining manufacturing and supply responsibilities. Under the agreement, Cipla gets exclusive marketing and distribution rights for Corex Dx, Corex LS, Dolonex and Neksium in India. Pfizer continues to manufacture, source and supply the medicines. This is an interesting business-model change. Pfizer already has more than 150 products across 16 therapeutic areas in India, with annual sales of over ₹2,000 crore. Its portfolio includes established brands such as Prevenar 13, Corex, Dolonex, Becosules and Folvite. The partnership allows Pfizer to use Cipla's distribution reach without transferring the manufacturing and supply side of the business. For an established-brand portfolio, distribution reach can be important because wider availability can directly influence prescription and retail sales. Pfizer has also been making organisational changes across its business, including a new leadership structure for vaccines and other therapy areas. **My view:** The Cipla partnership is more interesting as a strategy change than as a one-time corporate announcement. The key question is whether better distribution can revive growth from established brands while Pfizer continues building its higher-value portfolio I would watch sales growth of the partnered brands, Pfizer's product mix and whether similar partnerships are used for other mature brands. **What I'm watching:** revenue growth, established-brand performance, product mix, new partnerships and margins. **Stance:** The partnership should be judged by the incremental sales and profitability it creates, rather than simply the size of the brand portfolio covered. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

saurabh mittal

21 Sep • 7:31 AM · SEBI-Registered Analyst

Cipla Ltd new HER2‑bispecific ADC in‑license with SBP Group

CIPLA

Cipla’s U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license and supply a biosimilar of Merck’s Keytruda (pembrolizumab) in the United States, a move that expands Cipla’s oncology/specialty portfolio but has drawn caution from some brokers on competitive intensity. Separately, Cipla and the SBP Group signed an exclusive licensing agreement for a potential best‑in‑class HER2 bispecific ADC (Rolditamig Deuderuxtecan, TQB2102), further strengthening its oncology pipeline. On the corporate side, Cipla informed exchanges about an NCLT order (August 18, 2026) approving the merger of Inzpera Healthsciences Limited into Cipla, with notices issued to shareholders and creditors. Shares closed around ₹1,371–₹1,394 on September 18, with a 52‑week high near ₹1,526 and a market capitalisation of roughly ₹1.11 lakh crore.

Cipla Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Cipla Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Cipla Ltd.?

What is the market cap of Cipla Ltd.?

Should I buy Cipla Ltd. stock now?

What is the 52 week high and low of Cipla Ltd.?

Is the Cipla Ltd. stock good to buy?

Is Cipla Ltd. a good buy for the long term?

Is Cipla Ltd. overvalued or undervalued?

What is the PE and PB ratio of Cipla Ltd.?